Skip to main content
Brief Communications
November 27, 2001

Onset of multiple sclerosis associated with anti-TNF therapy

November 27, 2001 issue
57 (10) 1885-1888


Therapies aimed at inhibiting tumor necrosis factor (TNF), a proinflammatory cytokine implicated in autoimmune disease are effective, especially for rheumatoid arthritis. We report a patient with new onset MS closely associated with the initiation of anti-TNF therapy for juvenile rheumatoid arthritis. It is possible that the inhibition of TNF triggered MS in this individual.

Get full access to this article

View all available purchase options and get full access to this article.


Hohlfeld R. Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? Mult Scler . 1996; 1: 376–378.
Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature . 1995; 377: 348–351.
Segal BM, Cross AH. Fas(t) track to apoptosis in MS: TNF receptors may suppress or potentiate CNS demyelination. Neurology . 2000; 55: 906–907.
Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech . 2000; 50: 229–235.
Powell MB, Mitchell D, Lederman J, et al. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol . 1990; 2: 539–544.
Selmaj KW, Raine CS. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor anti-bodies and soluble tumor necrosis factor receptors. Neurology . 1995; 45 (6 suppl 6): S44–S49.
Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest . 1991; 87: 949–954.
The Lerencept Multiple Sclerosis Study Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology . 1999; 53: 457–465.
van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology . 1996; 47: 1531–1534.
Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Invest Drugs . 2000; 9: 497–514.

Information & Authors


Published In

Volume 57Number 10November 27, 2001
Pages: 1885-1888
PubMed: 11723281

Publication History

Received: June 20, 2001
Accepted: August 8, 2001
Published online: November 27, 2001
Published in print: November 27, 2001


Request permissions for this article.


Affiliations & Disclosures

Nancy L. Sicotte, MD
From the Division of Brain Mapping (Dr. Sicotte), Department of Neurology (Drs. Sicotte and Voskuhl), UCLA School of Medicine, Los Angeles, CA.
Rhonda R. Voskuhl, MD
From the Division of Brain Mapping (Dr. Sicotte), Department of Neurology (Drs. Sicotte and Voskuhl), UCLA School of Medicine, Los Angeles, CA.


Address correspondence and reprint requests to Dr. Nancy L. Sicotte, 710 Westwood Boulevard, Rm. A135, Los Angeles, CA 90095; e-mail: [email protected]

Metrics & Citations



Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Secondary Central Nervous System Demyelinating Disorders in the Elderly: A Narrative Review, Healthcare, 11, 15, (2126), (2023).
  2. Therapeutic potential of TNFR2 agonists: a mechanistic perspective, Frontiers in Immunology, 14, (2023).
  3. Inflammation-inducible promoters to overexpress immune inhibitory factors by MSCs, Stem Cell Research & Therapy, 14, 1, (2023).
  4. The TNFR1 antagonist Atrosimab reduces neuronal loss, glial activation and memory deficits in an acute mouse model of neurodegeneration, Scientific Reports, 13, 1, (2023).
  5. Discovery of a Non-competitive TNFR1 Antagonist Affibody with Picomolar Monovalent Potency That Does Not Affect TNFR2 Function, Molecular Pharmaceutics, 20, 4, (1884-1897), (2023).
  6. Clinical characteristics of intermediate uveitis in adults according to criteria of the SUN working group, International Ophthalmology, 43, 10, (3681-3693), (2023).
  7. Evaluation of Drugs and Strategies for Treating Coronary Artery Ectasia: Update and Future Perspective, Jundishapur Journal of Chronic Disease Care, 11, 3, (2022).
  8. Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review, Biomedicines, 10, 8, (2041), (2022).
  9. SOX-1 antibodies in a patient with Crohn’s disease: a case report, BMC Neurology, 22, 1, (2022).
  10. A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzheimer’s disease mouse model, Proceedings of the National Academy of Sciences, 119, 37, (2022).
  11. See more

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML







Share article link